Overview

The Study to YD312 Tablet in Patients With Diabetic Macular Edema

Status:
Active, not recruiting
Trial end date:
2020-03-20
Target enrollment:
Participant gender:
Summary
This study objectives is to evaluate the efficacy of YD312 to improve visual acuity in patients with diabetic macular edema (DME) compared to placebo and determine optimal dose of phase 2b study.
Phase:
Phase 2
Details
Lead Sponsor:
Se Hee Han
YD Global Life Science Co., Ltd.
Treatments:
Imatinib Mesylate